Integra LifeSciences (IART) Tops Q3 EPS by 14c

Integra LifeSciences (NASDAQ: IART) reported Q3 EPS of $0.86, $0.14 better than the analyst estimate of $0.72. Revenue for the quarter came in at $386.9 million versus the consensus estimate of $384.58 million.

GUIDANCE:

Integra LifeSciences sees FY2021 EPS of $3.16-$3.20, versus the consensus of $3.04. Integra LifeSciences sees FY2021 revenue of $1.54-1.55 billion, versus the consensus of $1.54 billion.

For earnings history and earnings-related data on Integra LifeSciences (IART) click here.

You May Also Be Interested In

• onsemi downgraded by TD Cowen after Synaptics deal clouds growth story
• SOL Strategies files amended Q2 fiscal 2026 interim financials
• SYNNEX Corp. (SNX) Tops Q2 EPS by 74c, Beats on Revenue; Offers Q3 Guidance